带状疱疹与带状疱疹后神经痛:常见问题解答
本文综述带状疱疹及带状疱疹后神经痛的常见临床问题。带状疱疹由潜伏水痘-带状疱疹病毒再激活引起,约三分之一人群会发病,皮疹多在2至4周内自愈。带状疱疹后神经痛是最常见并发症,发生于10%至18%的带状疱疹患者,定义为首发症状后持续超过90天的皮节疼痛综合征。治疗包括抗病毒药物联合或不联合辅助镇痛,带状疱疹后神经痛一线治疗为加巴喷丁类药物、5-羟色胺-去甲肾上腺素再摄取抑制剂和三环类抗抑郁药,重组带状疱疹疫苗可有效预防。
要点
- 约三分之一人群一生中会发生带状疱疹,皮疹通常2至4周自愈。
- 带状疱疹后神经痛发生于10%至18%的带状疱疹患者,定义为首发症状后持续超过90天。
- 重组带状疱疹疫苗推荐50岁及以上成人及19岁及以上免疫功能低下者接种两剂。
核心结论
- 带状疱疹及带状疱疹后神经痛可导致慢性功能损害,但通过接种重组带状疱疹疫苗在很大程度上可以预防。
研究设计与样本
- 本文为综述,汇总带状疱疹与带状疱疹后神经痛的常见临床问题及循证答案。
主要发现
- 约三分之一人群会发生带状疱疹,皮疹通常在2至4周内自愈。
- 带状疱疹后神经痛是最常见并发症,发生于10%至18%的带状疱疹患者。
- 老年人及免疫功能低下者发生带状疱疹及其并发症的风险更高。
关键数值与推荐
- 带状疱疹后神经痛定义为首发症状后持续超过90天的皮节疼痛综合征。
- 带状疱疹治疗使用抗病毒药物(如阿昔洛韦、伐昔洛韦、泛昔洛韦)联合或不联合辅助镇痛。
- 带状疱疹后神经痛一线治疗包括加巴喷丁类药物、5-羟色胺-去甲肾上腺素再摄取抑制剂和三环类抗抑郁药,外用药物为辅助治疗。
- 重组带状疱疹疫苗推荐50岁及以上成人及19岁及以上免疫功能低下者接种两剂。
临床怎么用
- 对带状疱疹患者应评估带状疱疹后神经痛风险,老年人及免疫功能低下者风险更高。
- 带状疱疹后神经痛一线治疗选用加巴喷丁类药物、5-羟色胺-去甲肾上腺素再摄取抑制剂或三环类抗抑郁药,外用药物作为辅助。
- 重组带状疱疹疫苗可预防带状疱疹及其并发症,医疗保险和商业保险覆盖。
局限性
- 接种障碍包括认知度低、接种操作错误、需多剂次接种及疫苗不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Herpes zoster (shingles) is the clinical manifestation of the reactivation of latent varicella-zoster virus from the dorsal root and cranial nerve ganglia. Approximately one-third of the population will develop herpes zoster, which most commonly results in a self-limited, painful, vesicular, dermatomal rash that resolves within 2 to 4 weeks. Complications of herpes zoster can result in chronic debility. Postherpetic neuralgia, a persistent dermatomal pain syndrome lasting longer than 90 days after symptom onset, is the most common complication, occurring in 10% to 18% of people who have herpes zoster. Older adults and immunocompromised individuals are at higher risk of developing herpes zoster and its associated complications. Treatment for herpes zoster involves antiviral medications (eg, acyclovir, valacyclovir, famciclovir) with or without adjunctive pain management. First-line treatment of postherpetic neuralgia includes gabapentinoids, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants. Topical drugs are an adjunctive treatment. Herpes zoster and its complications are largely preventable with vaccination (recombinant zoster vaccine), which is covered by Medicare and commercial insurances. Two doses of recombinant zoster vaccine are recommended for adults 50 years and older and those 19 years and older with immunocompromise. Obstacles to receiving vaccination include low awareness, administration errors, necessity of receiving multiple doses, and vaccine adverse effects.
引用
- Jones K, Keating M, Hansell M, et al. Herpes Zoster and Postherpetic Neuralgia: Common Questions and Answers. Am Fam Physician. 2026. PMID: 42789654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。